Trial · NCT02729896
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With CR at EOI, as Determined by the Investigator on the Basis of Positron Emission Tomography and Computed Tomography (PET-CT) Scan | Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 6 months) | Intent-to-treat (ITT) population: All participants who enrolled in the study were included in the ITT population. Data reported for all participants for whom data were available. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With CR at EOI, as Determined by Investigator on the Basis of CT Scans Alone | Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 6 months) | Intent-to-treat (ITT) population: All participants who enrolled in the study were included in the ITT population. Data reported for all participants for whom data were available. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Objective Response (CR + PR) at EOI, as Determined by the Investigator on the Basis of PET-CT Scans | Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 6 months) | Intent-to-treat (ITT) population: All participants who enrolled in the study were included in the ITT population. Data reported for all participants for whom data were available | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Objective Response (CR + PR) at EOI, as Determined by the Investigator on the Basis of CT Scans Alone | Within 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 6 months) | Intent-to-treat (ITT) population: All participants who enrolled in the study were included in the ITT population. Data reported for all participants for whom data were available | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Best Response of CR or PR During the Study, as Determined by the Investigator on the Basis of CT Scans Alone | Baseline up to 35 months | Intent-to-treat (ITT) population: All participants who enrolled in the study were included in the ITT population. Data reported for all participants for whom data were available | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Adverse Events and Serious Adverse Events | Baseline up to 35 months | The Safety Evaluable Population that includes patients who received at least one dose of any study treatment. | Percentage of participants | NUMBER |
| SECONDARY | Serum Obinutuzumab Concentration | Pre-dose (0 hr) up to 35 months | The Safety Evaluable Population that includes patients who received at least one dose of any study treatment. | mcg/mL | MEAN |
| SECONDARY | Serum Rituximab Concentration | Pre-dose (0 hr) up to 35 months | The Safety Evaluable Population that includes patients who received at least one dose of any study treatment. | mcg/mL | MEAN |
| SECONDARY | Serum Atezo Concentration | Pre-dose (0 hr) up to 35 months | The Safety Evaluable Population that includes patients who received at least one dose of any study treatment. | mcg/mL | MEAN |
| SECONDARY | Serum Pola Concentration | Pre-dose (0 hr) up to 35 months | The Safety Evaluable Population that includes patients who received at least one dose of any study treatment. | mcg/mL | MEAN |
| SECONDARY | Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab | Baseline up to 35 months | The Safety Evaluable Population that includes patients who received at least one dose of any study treatment. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Human Anti-Chimeric Antibodies (HACAs) to Rituximab | Baseline to 35 months | The Safety Evaluable Population that includes patients who received at least one dose of any study treatment. (FL cohorts not applicable as rituximab was only administered in the Safety Run- in phase). | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezo | Baseline to 35 months | The Safety Evaluable Population for this outcome measure includes participants in the DLBCL cohort who received at least one dose of any study treatment. Participants in the FL 1.4 mg and FL 1.8 mg were not anazlyed. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With ATAs to Pola | Baseline to 35 months | The Safety Evaluable Population that includes patients who received at least one dose of any study treatment. | Percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02729896/outcomes